CMRX vs. LFVN, QTTB, LPTX, AFMD, ETON, ALRN, IFRX, ONCY, RVPH, and MRNS
Should you be buying Chimerix stock or one of its competitors? The main competitors of Chimerix include LifeVantage (LFVN), Q32 Bio (QTTB), Leap Therapeutics (LPTX), Affimed (AFMD), Eton Pharmaceuticals (ETON), Aileron Therapeutics (ALRN), InflaRx (IFRX), Oncolytics Biotech (ONCY), Reviva Pharmaceuticals (RVPH), and Marinus Pharmaceuticals (MRNS). These companies are all part of the "pharmaceutical preparations" industry.
Chimerix (NASDAQ:CMRX) and LifeVantage (NASDAQ:LFVN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, community ranking, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.
In the previous week, Chimerix had 1 more articles in the media than LifeVantage. MarketBeat recorded 4 mentions for Chimerix and 3 mentions for LifeVantage. LifeVantage's average media sentiment score of 0.57 beat Chimerix's score of -0.10 indicating that LifeVantage is being referred to more favorably in the news media.
LifeVantage has higher revenue and earnings than Chimerix. Chimerix is trading at a lower price-to-earnings ratio than LifeVantage, indicating that it is currently the more affordable of the two stocks.
45.4% of Chimerix shares are owned by institutional investors. Comparatively, 35.3% of LifeVantage shares are owned by institutional investors. 10.0% of Chimerix shares are owned by insiders. Comparatively, 6.8% of LifeVantage shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Chimerix received 165 more outperform votes than LifeVantage when rated by MarketBeat users. However, 77.82% of users gave LifeVantage an outperform vote while only 64.12% of users gave Chimerix an outperform vote.
Chimerix presently has a consensus target price of $8.00, indicating a potential upside of 788.99%. Given Chimerix's higher possible upside, equities research analysts clearly believe Chimerix is more favorable than LifeVantage.
Chimerix has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. Comparatively, LifeVantage has a beta of 0.78, suggesting that its stock price is 22% less volatile than the S&P 500.
LifeVantage has a net margin of 1.40% compared to Chimerix's net margin of -25,337.96%. LifeVantage's return on equity of 19.96% beat Chimerix's return on equity.
Summary
LifeVantage beats Chimerix on 9 of the 17 factors compared between the two stocks.
Get Chimerix News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Chimerix Competitors List
Related Companies and Tools
